Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Lecanemab Alert: What Would Alzheimer's Drug Approval Mean for Biogen (BIIB) Stock?
02:07pm, Friday, 06'th Jan 2023
One stock that's trading in the right direction today is prominent mega-cap biotech stock Biogen (NASDAQ: BIIB ). Shares of BIIB stock have surged around 3.7% as of early afternoon trading on appare
Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?
11:20am, Friday, 06'th Jan 2023 Zacks Investment Research
Style Box ETF report for IMCV
Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?
10:41am, Friday, 06'th Jan 2023
Biogen stock jumped Friday ahead of an FDA decision on the accelerated approval of its experimental Alzheimer's treatment, lecanemab. The post Biogen Could Get A Second Alzheimer's OK — But Will Wil
1 Stock Defying the Downturn to Buy, and 1 to Avoid
09:53am, Friday, 06'th Jan 2023
These two stocks might go in different directions in the future.
Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments
08:46am, Friday, 06'th Jan 2023
CNBC's Meg Tirrell joins 'Squawk Box' to discuss the big day ahead for Alzheimer's medicine.
Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device
07:14pm, Thursday, 05'th Jan 2023 Zacks Investment Research
Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.
Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device
03:48pm, Thursday, 05'th Jan 2023
Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.
Could Eli Lilly Stock Help You Become a Millionaire?
03:07pm, Thursday, 05'th Jan 2023 The Motley Fool
Over the past 10 years, when including its dividend, Eli Lilly's total return has amounted to an incredible 843%.
Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemab
12:41pm, Thursday, 05'th Jan 2023 MarketWatch
A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021
Biogen Names Priya Singhal as Executive Vice President, Head of Development
12:30pm, Thursday, 05'th Jan 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of
Biogen separates research and development into two functions
08:03am, Thursday, 05'th Jan 2023
Biogen Inc. BIIB, -0.67% said Thursday that it separated research and development into two functions that report directly to new CEO Christopher Viehbacher. Priya Singhal, currently the head of global
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:00pm, Tuesday, 03'rd Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.
Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemab
02:47pm, Tuesday, 03'rd Jan 2023
The Food and Drug Administration is expected to make a decision on whether to approve a new Alzheimer's disease medication the week after a damning new report found the regulator didn't follow the cor
1 Large-Cap Biotech Stock to Buy for 2023 and Beyond
02:37pm, Tuesday, 03'rd Jan 2023 The Motley Fool
This company's best asset may be its pipeline.
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
